Press Releases

Press Releases

All Releases
Feb 24, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2013 , financial results will be released on Thursday, February 27, 2014 . Following the announcement, Ophthotech's management will host a live conference call and
Feb 18, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today the closing of its previously announced registered public offering of 2,628,571 shares of its common stock at a price to the public of $31.50 per share, before underwriting discounts.
Feb 11, 2014
New York, NY— Feb. 11, 2014 —Ophthotech Corporation (NASDAQ: OPHT) announced today the pricing of an underwritten public offering of 2,285,714 shares of common stock at a public offering price of $31.50 per share, before underwriting discounts.
Feb 10, 2014
Ophthotech Corporation Announces Proposed Public Offering of Common Stock New York, NY-Feb. 10, 2014 -Ophthotech Corporation (NASDAQ: OPHT) announced today that it has commenced an underwritten public offering of 1,900,000 shares of its common stock. In addition, certain stockholders of the company
Jan 24, 2014
Ophthotech Corporation Receives $41.7 Million in Second Tranche in Royalty Financing from Novo A/S New York, NY—January 24, 2014 —Ophthotech Corporation (Nasdaq: OPHT) today announced that it has received payment of approximately $41.7 million in a second tranche in royalty financing
Oct 30, 2013
Ophthotech to Report Third Quarter 2013 Results and Host Conference Call on Wednesday, November 13, 2013 NEW YORK, NY – October 30, 2013 – Ophthotech Corporation (Nasdaq: OPHT) today announced that the company will report its financial results for the third quarter ended September 30,
Sep 30, 2013
Ophthotech Closes Initial Public Offering NEW YORK, NY – September 30, 2013 – Ophthotech Corporation today announced the closing of its initial public offering of 8,740,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts, including
Sep 24, 2013
Ophthotech Corporation Prices Initial Public Offering NEW YORK, NY – September 24, 2013 – Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts.
Aug 29, 2013
Ophthotech Enrolls First Patient in Phase 3 Clinical Trial of Fovista™ Anti-PDGF Therapy in Combination with Anti-VEGF Therapy for Wet AMD New York, NY – August 29, 2013 – Ophthotech Corporation today announced the initiation of patient enrollment in a pivotal Phase 3 clinical
Aug 15, 2013
Ophthotech Corporation Files Registration Statement for Proposed Initial Public Offering New York, NY—August 15, 2013 – Ophthotech Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”)
Jan 03, 2013
Ophthotech to Present at 31st Annual J.P. Morgan Healthcare Conference Princeton, NJ and New York, NY – January 3, 2013 – Ophthotech Corp. announced today that the company will participate in the 31st Annual J.P. Morgan Healthcare Conference to be held Jan. 7-10, 2013.
Oct 24, 2012
Positive Results from Phase 2b Study of Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ to be Presented at AAO Retina Subspecialty Day Princeton, NJ – October 24, 2012 – Ophthotech Corporation today announced that data from a large, prospective, randomized,
Jan 03, 2012
Ophthotech to Present at 30th Annual J.P. Morgan Healthcare Conference Princeton, NJ and New York, NY – January 3, 2012 – Ophthotech Corp. announced today that the company will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco.